This is a prospective, multi-center, open-label, interventional phase IV clinical study. The study treatment i.e. brolucizumab will be prescribed in terms of the marketing authorization; the assignment of the patient to the therapy will be decided within the current practice and the medical indication, and will clearly be separated from the decision to include the patient in the study.~All patients with nAMD who are planned to be treated with brolucizumab and have provided informed consent may be enrolled in this study. The treatment period for each patient will be 56 weeks after the start of brolucizumab treatment. Study visits will be scheduled at week 4, week 8, week 16, and thereafter at intervals of 8 weeks or 12 weeks after disease activity assessment at week 16. If the investigators require more frequent follow-up visits, it can be done according to their discretion and clinical judgment. Any patient who suffers from intra-ocular inflammation (IOI) during the study period would not be re-challenged with brolucizumab.~Data originating from assessments and evaluations performed will be collected from the patient's medical records at Baseline (BL), i.e. start of brolucizumab treatment, week 4, week 8, week 16, week 20, week 24, week 32, week 40, week 44, week 48 and at week 56.
The purpose of this study is to generate additional safety and effectiveness data in Indian neovascular age-related macular degeneration (nAMD) patients that more closely resemble the real-world population intended to be treated with brolucizumab. This study is being conducted as part of the post-marketing regulatory commitment to the Indian Health authority.